相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes
S-I. Harashima et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes
Piero Ruggenenti et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
R. Kodera et al.
DIABETOLOGIA (2011)
Sitagliptin reduces albuminuria in patients with type 2 diabetes
Sachiko Hattori
ENDOCRINE JOURNAL (2011)
Management of type 2 diabetes: new and future developments in treatment
Abd A. Tahrani et al.
LANCET (2011)
Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression
Yuji Ishibashi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Rapid 'glycaemic swings' induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus
E. M. Horvath et al.
DIABETOLOGIA (2009)
Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation
Kristopher C. Dozier et al.
PEPTIDES (2009)
Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes - Preclinical biology and mechanisms of action
Daniel J. Drucker
DIABETES CARE (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin
G. A. Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients
F Pistrosch et al.
DIABETES (2005)
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
AS Go et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men
JP Gutzwiller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
M Yu et al.
JOURNAL OF HYPERTENSION (2003)
The effects of weight loss on renal function in patients with severe obesity
A Chagnac et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)
AI Adler et al.
KIDNEY INTERNATIONAL (2003)
分享论文
